MangoRx Board initiates strategic alternatives review to maximize shareholder value

MANGOCEUTICALS, INC.

Formalized $150K promissory note with CEO's entity Cohen Enterprises at 8% interest, due Jan 2, 2025.
Board formed strategy committee to explore mergers, acquisitions, divestitures, and business combinations.
Process is in parallel with current operations; no timeline or assurance of any transaction.
Company previously disclosed $50K loan from March 2024 and $100K loan from April 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.